Crossmark

Repurposing of FDA-approved Drugs Identifies Glipizide as a Potent HMG-CoA Reductase Inhibitor: a High-Throughput Virtual Screening and Molecular Dynamics Approach for Targeting Hypercholesterolemia

Crossref DOI link: https://doi.org/10.1007/s12247-025-10349-1

Published Online: 2026-01-12

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ahmad, Parvej https://orcid.org/0000-0002-3102-4369
Ghali, Eswara Naga Hanuma Kumar https://orcid.org/0000-0002-8005-7626
Alvi, Sahir Sultan https://orcid.org/0000-0002-5650-748X
Funding

Funding for this research was provided by:

Department of Health Research (DHR), Ministry of Health & Family Welfare (MoHFW), Govt. of India (12014/13/2019-HR)
License Information

Text and Data Mining valid from 2026-01-12

Version of Record valid from 2026-01-12
More Information

Article History

Received: 15 October 2025

Accepted: 21 December 2025

First Online: 12 January 2026

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below